ライフサイエンスコーパス: ulcerative

1 in size in 79.7% of patients and 93.2% were ulcerative.

2 Hemorrhagic cystitis is an inflammatory and ulcerative bladder condition associated with systemic ch

3 skin lesions of ulcerative CL (UCL) and non-ulcerative CL (NUCL) patients.

4 caused by L. tropica in the skin lesions of ulcerative CL (UCL) and non-ulcerative CL (NUCL) patient

5 s disease (hazard ratio 2.19; 1.44-3.34) and ulcerative colitis (hazard ratio 1.63; 1.18-2.27) was si

6 n sCDAI score 93 [IQR 47-156]), and 161 with ulcerative colitis (median P-SCCAI score 1 [IQR 1-3]).

7 uch (n = 27), normal pouch from patient with ulcerative colitis (n = 10), and normal pouch from patie

8 a diagnosis of Crohn's disease (n = 200) or ulcerative colitis (n = 199), as well as from 200 health

9 (RA, n = 229), Crohn's disease (n = 148), or ulcerative colitis (n = 36) treated with 8 different bio

10 g Cox regression separately in patients with ulcerative colitis (n = 4671), Crohn's disease (n = 3780

11 colon tissues from age-matched patients with ulcerative colitis (n=10) vs without IBD (n=8, controls)

12 ozanimod in patients with moderate-to-severe ulcerative colitis (n=179).

13 ated macular degeneration (P=1.4 x 10(-12)), ulcerative colitis (P<1.0 x 10(-20)), type 2 diabetes (P

14 ease (rg = 0.097 +/- 0.06, P = 3.27 x 10-3), ulcerative colitis (rg = 0.11 +/- 0.04, P = 4.05 x 10-3)

15 ide genetic correlation (rG) between PSC and ulcerative colitis (UC) (rG = 0.29) was significantly gr

16 odels for diagnosis of Crohn disease (CD) or ulcerative colitis (UC) among men and women aged 18-81 y

17 of 2017, we identified 323 incident cases of ulcerative colitis (UC) and 108 incident cases of Crohn'

18 AIMS: The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause s

19 al tract of uncertain origin, which includes ulcerative colitis (UC) and Crohn's disease (CD).

20 ase (PIBD), comprising Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease u

21 sylation is likely impaired in patients with ulcerative colitis (UC) and renders UC-HMA mice more sus

22 owel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC) and to compare the occurrence of

23 ng disease course and response to therapy in ulcerative colitis (UC) are not well understood.

24 etter understanding of prognostic factors in ulcerative colitis (UC) could improve patient management

25 Patients with ulcerative colitis (UC) experience periods of recurring

26 Although Crohn's disease (CD) and ulcerative colitis (UC) have been considered as disorder

27 s, incidence rates of Crohn disease (CD) and ulcerative colitis (UC) have been increased in epidemiol

28 Most patients with ulcerative colitis (UC) have mild-to-moderate disease ac

29 hat affect risk for Crohn's disease (CD) and ulcerative colitis (UC) in a case-only study of patients

30 ered 6-shogaol and its effectiveness against ulcerative colitis (UC) in a mouse model.

31 Incidence of ulcerative colitis (UC) in elderly population is increas

32 rrelated with development and progression of ulcerative colitis (UC) in human patients.

33 Ulcerative colitis (UC) is a chronic inflammatory bowel

34 Ulcerative colitis (UC) is a risk factor for colorectal

35 Ulcerative colitis (UC) is one of the main types of chro

36 Endoscopic disease activity scoring in ulcerative colitis (UC) is useful in clinical practice b

37 The odds of having ulcerative colitis (UC) or Crohn disease (CD) were eleva

38 mparisons of biologic treatment outcomes for ulcerative colitis (UC) or Crohn's disease (CD) patients

39 quencing, and measured the GMSI in 77 CD and ulcerative colitis (UC) patients (24 low and 53 normal G

40 specimens from 16 Crohn's disease (CD) and 6 ulcerative colitis (UC) patients and compared them to sa

41 d in colonic biopsies and blood samples from ulcerative colitis (UC) patients compared with healthy c

42 ive models of disease burden at diagnosis in ulcerative colitis (UC) patients for future use in popul

43 ospective study with Crohn's disease (CD) or ulcerative colitis (UC) patients initiating anti-integri

44 Similarly, ulcerative colitis (UC) patients responsive to fecal mic

45 ptom profiles among Crohn's disease (CD) and ulcerative colitis (UC) patients, respectively.

46 A subset of patients with ulcerative colitis (UC) present with, or progress to, mo

47 f human colonic CD8(+) T cells in health and ulcerative colitis (UC) using single-cell transcriptomic

48 esevoirs) in colectomy-treated patients with ulcerative colitis (UC) versus controls (familial adenom

49 s in inflammatory responses of patients with ulcerative colitis (UC) vs Crohn's disease (CD).

50 and TJP1) and IBD, Crohn's disease (CD), or ulcerative colitis (UC) were investigated.

51 stem was queried for hospital admissions for ulcerative colitis (UC) with concurrent colectomy and Cr

52 As is known, ulcerative colitis (UC), a chronic inflammatory disease,

53 c basis between CC and Crohn's disease (CD), ulcerative colitis (UC), and celiac disease.

54 main forms of irritable bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD).

55 nal ACE2 expression in Crohn's disease (CD), ulcerative colitis (UC), and non-inflammatory bowel dise

56 es (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are complex chronic inflammator

57 BDs), which include Crohn's disease (CD) and ulcerative colitis (UC), are multifactorial chronic cond

58 with inflammatory bowel diseases, including ulcerative colitis (UC), but the causality and mechanism

59 in has shown to be elevated in patients with ulcerative colitis (UC), Crohn's disease (CD) and colore

60 nal inflammation in Crohn's disease (CD) and ulcerative colitis (UC), in humans.

61 cohort study with 21 patients suffering from ulcerative colitis (UC), in which first-time treatment w

62 se (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a disease associated with dy

63 The economic burden of ulcerative colitis (UC), specifically related to indirec

64 transabdominal minimal invasive approach in ulcerative colitis (UC), using the comprehensive complic

65 ype 2 immune response in the pathogenesis of ulcerative colitis (UC)-few data are available from trea

66 (FMT) can induce remission in patients with ulcerative colitis (UC).

67 large randomized controlled trial of FMT for ulcerative colitis (UC).

68 tracheobronchitis is a rare complication of ulcerative colitis (UC).

69 n a distant background of surgically managed ulcerative colitis (UC).

70 tudies (GWAS) have revealed risk alleles for ulcerative colitis (UC).

71 sociated with the intestinal disease such as ulcerative colitis (UC).

72 with two subtypes, Crohn's disease (CD) and ulcerative colitis (UC).

73 has demonstrated efficacy in treating active ulcerative colitis (UC).

74 ncommon but life-threatening complication of ulcerative colitis (UC).

75 nosed with Crohn's disease (CD) and 361 with ulcerative colitis (UC).

76 signalling pathway has been associated with ulcerative colitis (UC).

77 -resistant colonic Crohn's disease (cCD) and ulcerative colitis (UC).

78 nastomosis (IRA) failure after colectomy for ulcerative colitis (UC).

79 ving pathways) contribute to pathogenesis of ulcerative colitis (UC).

80 n the intestinal microbiota of patients with ulcerative colitis (UC).

81 risk of developing Crohn's disease (CD) and ulcerative colitis (UC).

82 patients with moderately to severely active ulcerative colitis (UC).

83 ains histologic improvement in patients with ulcerative colitis (UC).

84 colonic mucosa [50 Crohn's disease (CD); 80 ulcerative colitis (UC); 31 controls].

85 om patients with Crohn's disease (n = 61) or ulcerative colitis (UC, n = 74) or from patients without

86 R, $87335-$126541]), and total colectomy for ulcerative colitis (WIQR, $24497; median, $34910 [IQR, $

87 disease +11.1% [95% CI 4.8-17.8] and APC for ulcerative colitis +14.9% [10.4-19.6]) and Taiwan (APC f

88 Crohn's disease +4.0% [1.0-7.1] and APC for ulcerative colitis +4.8% [1.8-8.0]).

89 2 per 100 000 in Germany) and North America (ulcerative colitis 286 per 100 000 in the USA; Crohn's d

90 HRs were increased for patients with ulcerative colitis 4.0, 95% CI 3.4-4.7; Crohn's disease

91 t reported prevalence values were in Europe (ulcerative colitis 505 per 100 000 in Norway; Crohn's di

92 h IBD (43 with Crohn's disease [CD], 23 with ulcerative colitis [UC]), and 30 children without IBD (c

93 ors and risk of IBD (Crohn's disease [CD] or ulcerative colitis [UC]).

94 535 consecutive patients with IBD (211 with ulcerative colitis [UC], 234 with Crohn's disease [CD];

95 roscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], a

96 h IBD (11 with Crohn's disease [CD], 13 with ulcerative colitis [UC], mean age 45 years [range 19-90]

97 nd Work Productivity and Activity Impairment-Ulcerative Colitis [WPAI-UC] questionnaire).

98 Guided by the Pediatric Ulcerative Colitis Activity Index (PUCAI), patients rece

99 nt (6 studies, N = 627; P = .035), Pediatric Ulcerative Colitis Activity Index score (4 studies, n =

100 Higher Pediatric Ulcerative Colitis Activity Index score and C-reactive p

101 Pouchitis that develops in patients with ulcerative colitis after total proctocolectomy and ileal

102 nflammatory bowel diseases (n = 119; 59 with ulcerative colitis and 60 with Crohn's disease).

103 mothers with Crohn disease (CD) and 194 with ulcerative colitis and 68,858 non-IBD mothers.

104 5, LRRK2, and MAPT for rheumatoid arthritis, ulcerative colitis and Crohn disease.

105 IBD consists of 2 subtypes: ulcerative colitis and Crohn disease.

106 To be included in the systematic review, ulcerative colitis and Crohn's disease needed to be repo

107 atory bowel disease (IBD), which consists of ulcerative colitis and Crohn's disease, are a significan

108 ammatory bowel diseases (IBD), that includes ulcerative colitis and Crohn's disease, can affect not o

109 hitecture of the inflammatory bowel diseases ulcerative colitis and Crohn's disease, we sequenced the

110 variety of clinical management scenarios for ulcerative colitis and Crohn's disease.

111 h as in inflammatory bowel disease including ulcerative colitis and Crohn's disease.

112 ing the notion of a disease continuum within ulcerative colitis and Crohn's disease.

113 th intestinal inflammatory diseases, such as ulcerative colitis and Crohn's disease.

114 bitor of MMP9, has shown promise in treating ulcerative colitis and gastric cancer.

115 ch as Crohn disease, multiple sclerosis, and ulcerative colitis and hereby elucidate the molecular me

116 80 in colonic epithelium of individuals with ulcerative colitis and in mice with experimentally induc

117 Mucosal biopsy specimens from patients with ulcerative colitis and inactive Crohn's disease have low

118 eir beneficial use in experimental models of ulcerative colitis and lung allograft rejection led us t

119 Intestine tissues from patients with ulcerative colitis and mice with colitis have increased

120 such as psoriasis, rheumatoid arthritis, and ulcerative colitis and neurological diseases such as amy

121 2 patients with quiescent Crohn's disease or ulcerative colitis and persistent gut symptoms at 2 larg

122 The T108M polymorphism is associated with ulcerative colitis and primary sclerosing cholangitis, i

123 licylate anti-inflammatory treatment against ulcerative colitis and sodium butyrate (NaB), a short ch

124 reased compared with patients with quiescent ulcerative colitis and that colitis was attenuated in IL

125 is, psoriatic arthritis, Crohn's disease, or ulcerative colitis and who were in commercial health pla

126 hin the intestinal epithelium of humans with ulcerative colitis and wild-type (WT) mice with experime

127 diseases (IBDs) such as Crohn's disease and ulcerative colitis are characterized by uncontrolled act

128 Crohn's disease and ulcerative colitis are chronic and progressive inflammat

129 Crohn's disease and ulcerative colitis are complex diseases that are heterog

130 Crohn's disease and ulcerative colitis are driven by both common and distinc

131 Crohn's disease and ulcerative colitis are heterogeneous inflammatory bowel

132 Crohn's disease and ulcerative colitis are the two forms of disorders of the

133 markers that can predict clinical outcome in ulcerative colitis at time of diagnosis.

134 y bowel disease (IBD) cohort and an in-house ulcerative colitis dataset, we shed light on the composi

135 ively, who had moderately to severely active ulcerative colitis despite previous conventional therapy

136 brilumab in patients with moderate-to-severe ulcerative colitis despite treatment with conventional t

137 ividuals vs patients with Crohn's disease or ulcerative colitis did not differ significantly after ex

138 copic, and histological data associated with ulcerative colitis disease activity in a composite index

139 y videos 1 endoscopic Mayo score (eMS) and 1 Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

140 ontaneous production of cytokines from human ulcerative colitis explants.

141 Intestinal tissues from patients with ulcerative colitis expressed significantly lower levels

142 ries, with a history (>/=3 months) of active ulcerative colitis extending more than 15 cm beyond the

143 nd perceptions of patients with acute severe ulcerative colitis following treatment with infliximab o

144 ncidence or prevalence of Crohn's disease or ulcerative colitis from 1990 or later.

145 atients aged 4-17 years with newly diagnosed ulcerative colitis from 29 centres in the USA and Canada

146 sk estimates of colorectal cancer related to ulcerative colitis from Asia vary.

147 se for terms related to colorectal cancer in ulcerative colitis from inception to July 1, 2016.

148 Conversely, patients with ulcerative colitis had an increased risk of liver diseas

149 from patients with CD and from patients with ulcerative colitis had distinct changes in DNA methylati

150 d submucosal tissue from patients with CD or ulcerative colitis had higher levels of collagens, inclu

151 lon tissues and organoids from patients with ulcerative colitis had increased levels of IL1B mRNA and

152 Ulcerative Colitis has similar presentation and behaviou

153 Previous retrospective studies of paediatric ulcerative colitis have had limited ability to describe

154 Patients with ulcerative colitis have mucosal inflammation starting in

155 Patients with Crohn's disease or ulcerative colitis have relatively high levels of stress

156 r disease and its frequent complication with ulcerative colitis highlights the pathogenic role of epi

157 potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.

158 with low gene dose, and the gut, developing ulcerative colitis in response to 1% dextran sulfate sod

159 Treatments for ulcerative colitis include 5-aminosalicylic acid drugs,

160 ons in adults hospitalized with acute severe ulcerative colitis included: (5) overall and comparative

161 Ulcerative colitis is a chronic inflammatory disease aff

162 The therapeutic armamentarium for ulcerative colitis is expanding, and the number of drugs

163 nditions in patients with Crohn's disease or ulcerative colitis is necessary for their total care and

164 ion and maintenance therapy in patients with ulcerative colitis is unknown.

165 The increased risk of colorectal cancer in ulcerative colitis is well known.

166 onic tissues from human subjects with active ulcerative colitis or Crohn's disease, implicating the l

167 amples from patients with Crohn's disease or ulcerative colitis or healthy individuals (controls).

168 The 14 patients with monogenic ulcerative colitis or IBD-unclassified received their di

169 rs, 69.9% had Crohn's disease, and 30.1% had ulcerative colitis or IBD-unclassified; median follow-up

170 %) had Crohn's disease, and 1451 (43.0%) had ulcerative colitis or unclassified inflammatory bowel di

171 1 patients with Crohn's disease and 102 with ulcerative colitis participated.

172 of TRIM58 in myeloid cells may contribute to ulcerative colitis pathogenesis.

173 onomycin, TNF-alpha, or H(2)O(2), PBMCs from ulcerative colitis patients treated with NX-13 had decre

174 More polyps were present in the ulcerative colitis patients when compared to Crohn's dis

175 in mouse models and human primary cells from ulcerative colitis patients with effects on NF-kappaB ac

176 Host & Microbe, Leonardi et al. demonstrate ulcerative colitis patients with high Candida responded

177 In four of the five ulcerative colitis patients, biopsies taken after 7d dos

178 uded healthy volunteers, Crohn's disease and ulcerative colitis patients.

179 Genome-wide association studies in ulcerative colitis point to a role for FcgammaRIIA, a re

180 hn's disease and 15 (83.3%) of 18 studies on ulcerative colitis reported stable or decreasing inciden

181 viduals and patients with Crohn's disease or ulcerative colitis secreted IL22, which promoted barrier

182 tify serum biomarkers of Crohn's disease and ulcerative colitis that can be detected and quantified b

183 al signatures holds the promise of informing ulcerative colitis therapeutic decisions.

184 in adults with moderately to severely active ulcerative colitis to determine whether vedolizumab was

185 he response of children newly diagnosed with ulcerative colitis to standardised initial therapy and i

186 Ulcerative colitis usually presents with bloody diarrhoe

187 lammatory polyps, family history of CRC, and ulcerative colitis versus Crohn's disease was considered

188 found no difference between individuals with ulcerative colitis vs Crohn's disease.

189 of IL19 in biopsies of patients with active ulcerative colitis was increased compared with patients

190 of colorectal cancer in Asian patients with ulcerative colitis was similar to recent estimates in Eu

191 Former smokers with ulcerative colitis were at increased risk of colectomy (

192 Treatment naive-patients with ulcerative colitis were included at time of initial diag

193 dred seventy patients with steroid-resistant ulcerative colitis were randomised to either infliximab

194 miRNA signature identified in mice predicted ulcerative colitis with 83.3% accuracy.

195 sis included a total of 31 287 patients with ulcerative colitis with a total of 293 reported colorect

196 ntified patients who received a diagnosis of ulcerative colitis within 5 years with an AUROC of only

197 of IBD (71 with Crohn's disease and 41 with ulcerative colitis) and 19 children without IBD (control

198 ith IBD (30 with Crohn's disease and 27 with ulcerative colitis) and 30 patients without IBD (control

199 the backdrop of an inflamed mucosa (e.g. in ulcerative colitis) remains exceedingly difficult.

200 variate, Crohn's disease and no IBD (both vs ulcerative colitis) were associated with a lower risk of

201 ents with IBD and colorectal cancer (15 with ulcerative colitis, 14 with Crohn's disease, and 2 with

202 ected in intestinal samples of patients with ulcerative colitis, a condition associated with increase

203 nd their metabolism is often dysregulated in ulcerative colitis, a major category of inflammatory bow

204 diseases, which include Crohn's disease and ulcerative colitis, affect several million individuals w

205 with Crohn's disease (CD), 48 patients with ulcerative colitis, and 26 patients without inflammatory

206 Crohn's disease, 19/100,000 person-years for ulcerative colitis, and 5/100,000 person-years for IBD u

207 on, a collagen-induced arthritis, an induced ulcerative colitis, and an ovalbumin-induced allergic co

208 ay a major role in the immunopathogenesis of ulcerative colitis, and anti-TNF antibodies are consider

209 increased susceptibility to Crohn's disease, ulcerative colitis, and asthma.

210 iota density was reduced in Crohn's disease, ulcerative colitis, and ileal pouch-anal anastomosis.

211 disease (IBD), including Crohn's disease and ulcerative colitis, and in 2,4,6-trinitrobenzene sulfoni

212 f recovery from bone marrow transplantation, ulcerative colitis, and partial hepatectomy.

213 lved in the pathogenesis of Crohn's disease, ulcerative colitis, and pouchitis.

214 seases (IBDs), including Crohn's disease and ulcerative colitis, are associated with dysbiosis of the

215 el diseases (IBD), such as Crohn disease and ulcerative colitis, are chronic relapsing conditions tha

216 sive analysis spanning prediction tasks from ulcerative colitis, atopic dermatitis, diabetes, to many

217 Tofacitinib is effective in treatment of ulcerative colitis, but there are safety concerns.

218 ative regulator of innate immunity) in human ulcerative colitis, by comparing monozygotic twins and o

219 atures for different IBD subtypes, including ulcerative colitis, colonic Crohn's disease and ileal Cr

220 uced colitis and human colonic biopsies from ulcerative colitis, compared with controls.

221 identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowe

222 lammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel di

223 Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel di

224 n mucosal integrity has been associated with ulcerative colitis, Crohn's disease and potentially coul

225 tablished common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel

226 patients with moderately to severely active ulcerative colitis, etrasimod 2 mg was more effective th

227 For patients with ulcerative colitis, Eubacterium rectale and Akkermansia

228 of CCDC88b in patients with Crohn disease or ulcerative colitis, identifying that expression correlat

229 anti-tumor necrosis factor (TNF) therapy in ulcerative colitis, its effects on postoperative outcome

230 rhea (ICD) in rhesus macaques also resembles ulcerative colitis, one form of human inflammatory bowel

231 ears old or younger and had Crohn's disease, ulcerative colitis, or IBD-unclassified with 24,543.0 pa

232 Defined as a diagnosis of Crohn's disease, ulcerative colitis, or inflammatory bowel disease unclas

233 tween PD and type 1 diabetes, Crohn disease, ulcerative colitis, rheumatoid arthritis, celiac disease

234 bowel disease including Crohn's disease and ulcerative colitis, the arthritis related to anterior uv

235 In ulcerative colitis, the association was not significant.

236 Further, in patients with ulcerative colitis, the concentration of active IL-18 wa

237 With the exception of ulcerative colitis, the degree and direction of these ge

238 estigated to delineate mechanisms regulating ulcerative colitis, the role of acid ceramidase (AC) in

239 patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as in

240 d in early clinical studies for treatment of ulcerative colitis, using conditions that mimic the huma

241 patients with moderately to severely active ulcerative colitis, vedolizumab was superior to adalimum

242 nflammatory bowel diseases-Crohn disease and ulcerative colitis-caused by untoward reactivity of the

243 healing in patients with moderate-to-severe ulcerative colitis.

244 nce that could used in early phase trials of ulcerative colitis.

245 et engagement assessed in five patients with ulcerative colitis.

246 emission in patients with moderate-to-severe ulcerative colitis.

247 nding in mucosal biopsies from patients with ulcerative colitis.

248 I), and height, but not for Crohn disease or ulcerative colitis.

249 reported in patients with Crohn's disease or ulcerative colitis.

250 uced in colonic specimens from patients with ulcerative colitis.

251 274 paediatric patients with newly diagnosed ulcerative colitis.

252 ged about how people adjusted to living with ulcerative colitis.

253 l disease (IBD) includes Crohn's disease and ulcerative colitis.

254 one in children who are newly diagnosed with ulcerative colitis.

255 differentiated colitis, Crohn's disease, and ulcerative colitis.

256 c therapies are widely used in patients with ulcerative colitis.

257 therapy in patients with moderate-to-severe ulcerative colitis.

258 ens in children who are newly diagnosed with ulcerative colitis.

259 3% and 0.7% (odds ratio 1.75; 1.44-2.13) for ulcerative colitis.

260 se variant in ADCY7 that doubles the risk of ulcerative colitis.

261 ged 4-17 years who were newly diagnosed with ulcerative colitis.

262 to identify patients 18 years or older with ulcerative colitis.

263 human patients with Clostridium difficile or ulcerative colitis.

264 in gut mucosa among associations stronger in ulcerative colitis.

265 emission in patients with moderate to severe ulcerative colitis.

266 evalence (69 studies) of Crohn's disease and ulcerative colitis.

267 trials of tofacitinib therapy in adults with ulcerative colitis.

268 mine serves as the gold standard in treating ulcerative colitis.

269 hose patients hospitalized with acute severe ulcerative colitis.

270 on the risk of colorectal cancer related to ulcerative colitis.

271 ies for psoriasis, rheumatoid arthritis, and ulcerative colitis.

272 ransplantation and response to Infliximab in ulcerative colitis.

273 l Modification (ICD-9-CM) diagnosis code for ulcerative colitis.

274 00547659 in patients with moderate to severe ulcerative colitis.

275 e patients had Crohn's disease, and half had ulcerative colitis.

276 ta has recently been successfully applied to ulcerative colitis.

277 ies evaluated adults with Crohn's disease or ulcerative colitis.

278 nvironmental influences, such as diabetes or ulcerative colitis.

279 omarkers associated with future diagnosis of ulcerative colitis.

280 ctivity in patients with Crohn's disease and ulcerative colitis.

281 and organoids from patients with and without ulcerative colitis.

282 cidence similar to that of Crohn disease and ulcerative colitis.

283 Australia (23 with Crohn's colitis, 29 with ulcerative colitis; median age, 45.0 y; 60% male; mean I

284 Mouth ulcers are the most common ulcerative condition and encompass several clinical diag

285 Ketamine-induced ulcerative cystitis (KIC) initially damaged the bladder

286 A distinct ulcerative dermatitis known as "freshwater skin disease"

287 usly associated with two other oropharyngeal ulcerative disorders, Behcet's disease and recurrent aph

288 has not been reported in case of peripheral ulcerative keratitis (PUK).

289 alization after ~4 months) and a superficial ulcerative lesion in a control group patient (conservati

290 in S (SLS)-mediated hemolysis, and localized ulcerative lesion progression during subcutaneous infect

291 , grade of lesion extension, and presence of ulcerative lesion were significantly associated with gin

292 V-1) and HSV-2 and are significant causes of ulcerative mucosal sores, infectious blindness, encephal

293 and 49 of the postmenopausal women developed ulcerative mucositis (p = 0.769), more often with lympho

294 was collected and the presence or absence of ulcerative oral mucositis (UOM) was scored (WHO scale).

295 crobiome, while patients who did not develop ulcerative oral mucositis had a more resilient microbial

296 al changes in relation to the development of ulcerative oral mucositis in autologous SCT (autoSCT) re

297 /48 patients respectively, P=0.31) showed an ulcerative perforation in a high power group patient (tr

298 sh populations following the emergence of an ulcerative skin disease in August 2017, when estimated d

299 by vasculopathy, interstitial lung disease, ulcerative skin lesions, and premature death.

300 s invadans, the causative agent of epizootic ulcerative syndrome, is one of the most destructive path